Workpackage 04

Objectives of the Workpackage

• Establishment of cross-species functional connectivity imaging in humans and rodents.
• Establishment of human cognitive neuroimaging paradigms for drug discovery.
• Testing of the fMRI activation paradigms in genetically susceptible subjects.
• Validation of the cross-species connectivity models for drug discovery.
• Validation of the cognitive neuroimaging paradigms for drug discovery.

Workpackage Leads

Academic Lead: Prof. Andreas Meyer-Lindenberg,  Zentralinstitut fuer Seelische Gesundheit (Central Institute of Mental Health), Germany
EFPIA Lead: Dr. Adam Schwarz, Eli Lilly and Company Limited, US

Workpackage Partners

• H. Lundbeck A/S
• King’s College London
• Central Institute of Mental Health 
• Pfizer Limited
• F. Hoffmann-La Roche AG
• Institut de Recherches Servier

Synergy between academia and industry

This workpackage brings together academic partners with unique expertise in translational imaging with industry expertise in therapy research for schizophrenia and depression. Specific interests and expertise of GSK in the domain of human cognitive neuroimaging will dovetail with the academic interests in using these paradigms for the delineation of prefrontal-subcortical risk mechanisms. Both GSK and Roche have large expertise in rodent neuroimaging at 4.7 Ts and ASL that will combine.